Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Stephen V. Liu, Martin Reck, Aaron S. Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier de Castro, Raffaele Califano, Makoto Nishio, Francesco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong Seok Lee, Sivuonthanh Lam, Mark L. McCleland, Yu Deng, See Phan, Leora Horn

Journal of Clinical Oncology, 2021

Bayer (United States), Pfizer (United States), Georgetown University, Georgetown University Medical Center, Boehringer Ingelheim (Philippines), AstraZeneca (Canada), Xcovery (United States), LungenClinic Grosshansdorf, Mayo Clinic in Arizona, Chinese University of Hong Kong, Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, Asklepios Fachkliniken München-Gauting, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research, University of Manchester, The Christie NHS Foundation Trust, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Instituto Nacional del Tórax, University of Wisconsin Carbone Cancer Center, Jilin Province Tumor Hospital, Seoul National University Bundang Hospital, Vanderbilt University Medical Center

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with Journal of Clinical Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

788

Citations

View on Google Scholar

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Abstract

Journal Details

Join JournalsHub

Welcome Back